Flow immunophenotyping features of crisis phase of chronic myeloid leukemia in childhood: do we really care?

  • Dr Namrata N Rajkumar Assistant Professor of Pathology, Kidwai Memorial Institute of Oncology Bangalore, Karnataka, India
  • Dr Raghavendra H .V. Associate Professor of Pathology, Kidwai Memorial Institute of Oncology Bangalore, Karnataka, India
  • Dr Vijay C. Raghu Assistant Professor, Department Biostatistics, Kidwai Memorial Institute of Oncology Bangalore, Karnataka, India
  • Dr Lakshmiah K Chinnagiriyappa Prof & head Department of Medical Oncology, Kidwai Memorial Institute of Oncology Bangalore, Karnataka, India
DOI: https://doi.org/10.17511/ijmrr.2016.i03.31
Keywords: CML: chronic myeloid leukemia, childhood, polymerase chain reaction, FCI: Flowcytometry immunophenotyping, Blastic phase

Abstract

Objective: Chronic leukemias are rare in childhood & CML is extremely rare in children. Imunophenotypic studies have a limited role in the diagnosis of CML but are increasingly being used in CML blast transformation. Purpose of the study was determine the clinical and laboratory and Flow immunophenotyping (FIC) features with Mutational analysis of blast transformation of CML in children.

Methods: 11 years analysis was done 187 cases of suspected CML were studied in children and adolescents. Patients were evaluated at KMIO between 2004 to 2015. 97 cases had Bone marrow diagnosis of CML. 22 cases peripheral smear was suggestive of blastic phase CML (20 %) were chosen for the study. Bone marrow confirmation was available in all the cases. Cytogenetics and Molecular confirmation was also available in all cases. FIC was done in 8/22(36%) cases. Mutations were studied in 7 cases.

Results: The disease predominantly affected older children more than 10 years 16/22(72 %). Male sex predilection was seen. Gender ratio was 1.4: 1. Most predominant clinical sign was splenomegaly. Leucocyte count>100X109/L was seen in all cases. Peripherals smear suggested CML in all 22cases and bone marrow aspiration confirmed the diagnosis.17 Cases were at diagnosis. 5 Cases progressed to blastic phase from chronic phase. Median year of transformation was 4 years. In 22 cases Phildelphia chromosome was noted and 5 cases revealed additional markers PCR revealed p210 transcript in all cases. In 8 cases in the blastic phase Flow cytometry immunophenotype was done. 5 cases were myeloid blastic phase, single case was mixed phenotype, 2 cases were lymphoid blastic phase.

Conclusion: Imatinib highly effective in children with advanced phase of CML. This is the largest, exclusive first reported series of blastic phase of CML in children from a single center. Only 5 cases received Imatinib, All 5cases attained remission; Cases are on follow up and continue to be in remission after a mean of 6 months.

Downloads

Download data is not yet available.

References

1. J W Vardiman,J.V.Melo,M.Baccarani,J.Thiele. Chronic Myeloid Leukemia,BCR-ABL1 positive. WHO classification of hematopoietic and lymphoid tissue 4th ed.IARC,Lyon,France:2008.pp 32-37.

2. Alkhatib MA. Pattern of pediatric chronic myeloid leukemia in Sudan and hematological response to imatinib. Pediatr Hematol Oncol. 2011 Mar;28(2):100-5. doi: 10.3109/08880018.2010.512949. Epub 2010 Nov 17.

3. Philip A Pizzo,David G Poplock.Principles and practice of pediatric oncology .Arnold J Altman.Cecilia FN. Chronic leukemias of childhood 6TH edition .Lippincott Williams and wilkins.2011:611-637.

4. K Ganessan , RuchikaGoel,Kamleshkumar,SameerBakshi.Biphenotypic extramedullary blast crisis as a presenting manifestation of Phildelphia chromosome –Positive CML in a child.Pediatric Hematology and Oncology .2007;24:195-198.

5. LarsonRS,Wolff SN.Chronic Myeloid Leukemia. In: LeeGR, forester J,LukensJ, paraskeras F,GreerJP, Rodgers GM,eds .Wintrobe’s clinical hematology,10thed.Baltimore:Williams&Wilkin’s;1999:2342-2373.

6. Raut L, Bohara VV, Ray SS, Chakrabarti P, Chaudhuri U. Chronic myeloid leukemia in children and adolescents: A single center experience from Eastern India. South Asian J Cancer. 2013 Oct;2(4):260-4. doi: 10.4103/2278-330X.119891.

7. LalitRaut .Chronic myeloid leukemia in children A brief review.Clin Cancer Investigation journal.2014;3:467-471.

8. Stefan Faderl, ZeevEstrovRazelleKurzrock ,hagop M K antarjian .The biology of Chronic Myeloid Leukemia.The New England Journal of Medicine.1999;15;165-172.

9. ThomasErnsrt and Andreas Hochhaus . Chronic Myeloid Leukemia:Clinical impact of BCR-ABL1 Mutations and other lesions Associated With Disease Progression. Seminars in Oncology.2012;39:58-66.

10. Goldman JM, Melo JV. Chronic myeloid leukemia--advances in biology and new approaches to treatment. N Engl J Med. 2003 Oct 9;349(15):1451-64. [PubMed]

11. Dikshit RP, Nagrani R, Yeole B, Koyande S, Banawali S. Changing trends of chronic myeloid leukemia in greater Mumbai, India over a period of 30 years. indian J Med Paediatr Oncol. 2011 Apr;32(2):96-100. doi: 10.4103/0971-5851.89792. [PubMed]

12. Millot F, Traore P, Guilhot J, Nelken B, Leblanc T, Leverger G, Plantaz D, Bertrand Y, Bordigoni P, Guilhot F. Clinical and biological features at diagnosis in 40 children with chronic myeloid leukemia. Pediatrics. 2005 Jul;116(1):140-3.

13. Ching-Hon Pui, Childhood Leukemias.The New England Journal Of Medicine.1995;332:1620-1628.

14. Wechalekar AD, Parande CM. Haematological malignancies in developing countries: is CML the commonest childhood leukaemia? Leukemia. 2007 Oct;21(10):2194; author reply 2195. Epub 2007 Aug 2.

15. Millot F ,GuilhotJ, NelkenB,LeblancT,DeBontES,BekassyAN,et al Imatinibmesylate is effective in children with Chronic Myelogenous Leukemia in late chronic and advanced phase and in relapse after stem cell transplantation.Leukemia.2006;20:187-92. [PubMed]

16. Castro-Malaspina H, Schaison G, Briere J, Passe S, Briere J, Pasquier A, Tanzer J, Jacquillat C, Bernard J. Philadelphia chromosome-positive chronic myelocytic leukemia in children. Survival and prognostic factors. Cancer. 1983 Aug 15;52(4):721-7.

17. Khalidi HS, Brynes RK, Medeiros LJ, Chang KL, Slovak ML, Snyder DS, Arber DA. The immunophenotype of blast transformation of chronic myelogenous leukemia: a high frequency of mixed lineage phenotype in "lymphoid" blasts and A comparison of morphologic, immunophenotypic, and molecular findings. Mod Pathol. 1998 Dec;11(12):1211-21.

18. Voican I, Vlădăreanu AM, Bumbea H, Begu M. Sudden blast crisis in a chronic myeloid leukemia patient during imatinib therapy. Rom J Intern Med. 2012 Jul-Sep;50(3):241-4.

19. Kim AS, Goldstein SC, Luger S, Van Deerlin VM, Bagg A. Sudden extramedullary T-lymphoblastic blast crisis in chronic myelogenous leukemia: a nonrandom event associated with imatinib? Am J Clin Pathol. 2008 Apr;129(4):639-48. doi: 10.1309/GTGTEQAFMV30W753.

20. Thota NK, Gundeti S, Linga VG, Coca P, Tara RP; Raghunadharao. Imatinib mesylate as first-line therapy in patients with chronic myeloid leukemia in accelerated phase and blast phase: a retrospective analysis. Indian J Cancer. 2014 Jan-Mar;51(1):5-9. doi: 10.4103/0019-509X.134598.

21. Belgaumi AF, Al-Shehri A, Ayas M, Al-Mahr M, Al-Seraihy A, Al-Ahmari A, El-Solh H. Clinical characteristics and treatment outcome of pediatric patients with chronic myeloid leukemia. Haematologica. 2010 Jul;95(7):1211-5. doi: 10.3324/haematol.2009.015180. Epub 2010 Apr 21.

22. Andolina JR, Neudorf SM, Corey SJ. How I treat childhood CML. Blood. 2012 Feb 23;119(8):1821-30. doi: 10.1182/blood-2011-10-380774. Epub 2011 Dec 30.
Flow immunophenotyping features of crisis phase of chronic myeloid leukemia in childhood: do we really care?
CITATION
DOI: 10.17511/ijmrr.2016.i03.31
Published: 2016-03-31
How to Cite
1.
N Rajkumar N, H .V. R, C. Raghu V, K Chinnagiriyappa L. Flow immunophenotyping features of crisis phase of chronic myeloid leukemia in childhood: do we really care?. Int J Med Res Rev [Internet]. 2016Mar.31 [cited 2024Apr.16];4(3):463-9. Available from: https://ijmrr.medresearch.in/index.php/ijmrr/article/view/500
Issue
Vol 4 No 3 (2016): MARCH
Section
Original Article

Most read articles by the same author(s)